#ASCO22: Rare biomarker leads to ‘unprecedented’ results in small rectal cancer study
In an ongoing, 18-person study, every single patient that has completed treatment saw their rectal cancer completely disappear.
None of them needed chemotherapy, radiation, or surgery — the combination that makes up the standard of care for rectal cancer.
Instead, the patients were treated with a six-month course of dostarlimab, the PD-1 antibody marketed as Jemperli that GSK acquired when it bought Tesaro in 2018. The prerequisite for receiving Jemperli, however, was that patients had early-stage, localized rectal cancer with a rare biomarker known as mismatch repair-deficient (MMR-deficient).
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.